Antitrypsin Deficiency Stocks List Ranked for 2024

Symbol	Grade	Name	% Change
ALNY	A	Alnylam Pharmaceuticals, Inc.	0.43
BEAM	D	Beam Therapeutics Inc.	4.03
KMDA	D	Kamada Ltd.	3.00
BAX	F	Baxter International Inc.	0.94
INBX	F	Inhibrx, Inc.	-0.88
NTLA	F	Intellia Therapeutics, Inc.	3.61

Related Industries: Biotechnology Medical Instruments & Supplies

Symbol	Grade	Name	Weight
GNOM	D	Global X Genomics & Biotechnology ETF	13.64
GERM	D	ETFMG Treatments Testing and Advancements ETF	10.46
ARKG	F	ARK Genomic Revolution Multi-Sector ETF	8.46
FBT	B	First Trust Amex Biotech Index Fund	8.17
BTEC	C	Principal Healthcare Innovators Index ETF	6.21

Compare ETFs

Compare FBT to BTEC Compare GNOM to FBT Compare GNOM to GERM

Date	Stock	Title
Jul 3	KMDA	Kamada draws Buy at Stifel on underappreciated component
Jul 3	NTLA	Cathie Wood's Ark Invest Sells Tesla Shares Worth $14.5M Amid Rally Driven By Q2 Delivery Numbers, Picks Up Palantir Shares Again Today
Jul 2	NTLA	3 Stocks Cathie Wood Just Bought to Get Back on Track in the Second Half of 2024
Jul 1	BEAM	Beam Therapeutics: Slow Developmental Progress, But Promising Potential
Jul 1	ALNY	Alnylam, Lilly, AstraZeneca among best performing pharmas, biotechs in Q2
Jun 30	ALNY	Rivian Automotive And Carvana Were Among The 10 Biggest Large Cap Gainers Last Week (June 23-June 29): Are These In Your Portfolio?
Jun 29	ALNY	Selling US$7.7m Of Alnylam Pharmaceuticals Stock Rewarded Insiders
Jun 27	BAX	Did Baxter International Inc. (BAX) Beat the Market in Q1?
Jun 27	ALNY	Peering Into Alnylam Pharmaceuticals's Recent Short Interest
Jun 27	ALNY	Biotech Stock Roundup: ALNY Up on Study Success, ALIM on Merger News & Other Updates
Jun 27	NTLA	Intellia (NTLA) Shares Fall as CFO Glenn Goddard Steps Down
Jun 27	BEAM	Beam Therapeutics (BEAM) Begins Dosing in Phase I/II AATD Study
Jun 27	BAX	Wall Street Breakfast Podcast: SpaceX Said To Hit $210B Valuation, Wins $843M NASA Deal
Jun 27	BAX	Baxter issues Class 1 recall of Life2000 ventilators over battery charging issue
Jun 27	NTLA	Cathie Wood's Ark Invest Acquires $7.3M Worth Of Shares In This Promising Netflix Competitor, Sells Off Coinbase Stock Amid Bitcoin Slump
Jun 27	NTLA	Rags to Riches: 3 Gene Editing Stocks That Could Make Early Investors Rich

Antitrypsin Deficiency: Antitrypsin Deficiency is a genetic disorder that affects the lungs and liver. It is caused by a deficiency of the protein alpha-1 antitrypsin (AAT), which is produced in the liver and helps protect the lungs from damage. People with Antitrypsin Deficiency are at an increased risk of developing lung diseases such as emphysema and chronic obstructive pulmonary disease (COPD). They may also be at risk of developing liver disease. Treatment for Antitrypsin Deficiency includes lifestyle changes, medications, and in some cases, a liver transplant.